Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RPA1 | P27694 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | VDR | P11473 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21716506 | 0.99 | MEN1 (0.35) | MEN1KMT2AATMABCG2CYP1A2 | |
| SCHEMBL21717192 | 0.96 | RPA1 (0.33) | MEN1KMT2AATMHPGDRPA1 | |
| SCHEMBL21717679 | 0.95 | MEN1 (0.31) | MEN1KMT2AATM | |
| SCHEMBL21717675 | 0.95 | RPA1 (0.35) | MEN1KMT2AATMHPGDRPA1 | |
| SCHEMBL21716328 | 0.94 | MEN1 (0.31) | MEN1KMT2AATM | |
| SCHEMBL21717071 | 0.94 | MEN1 (0.34) | MEN1KMT2AATMHPGDRPA1 | |
| SCHEMBL21213785 | 0.90 | ATM (0.39) | MEN1KMT2AATMHPGDRPA1 | |
| SCHEMBL21716590 | 0.90 | RPA1 (0.32) | MEN1KMT2AATMHPGDRPA1 | |
| SCHEMBL21716880 | 0.89 | RPA1 (0.32) | MEN1KMT2AATMHPGDRPA1 | |
| SCHEMBL21717154 | 0.89 | HPGD (0.31) | HPGDRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192884-B2 | Heterocyclic compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2021-12-07 | — | — | US | disclosed |
| US-20200048226-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192884-B2 | Heterocyclic compound and organic light-emitting device comprising same | CYP1A1, CYP1B1, CRY1 | MEN1 200/4885KMT2A 878/4885ATM 3428/4885 |
| US-20200048226-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CYP1A1, CYP1B1, CRY1 | MEN1 200/4885KMT2A 878/4885ATM 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.